Aze Wilson

Aze Wilson

Assistant Professor

PH.D. Western University
MD Western University
Office: LHSC-University Hospital
p. 519.663.3832

Dr. Aze Wilson is a clinical gastroenterologist and an Assistant Professor of Medicine at Western University.  She joined the Division of Gastroenterology in 2016 as a Clinician-Researcher with a focus on translational research in inflammatory bowel disease.  She has a cross-appointment with the Division of Clinical Pharmacology and the Department of Physiology & Pharmacology.  Dr. Wilson began her scientific training at Queen's University, where she completed an honours BSc. in Life Sciences.  She completed her medical education at Western University, becoming accredited in both Internal Medicine and Gastroenterology.  She completed the Royal College-certified Clinician-Investigator Program in 2016 in addition to completing her PhD in Physiology and Pharmacology.  Her clinical interests include inflammatory bowel disease and other luminal diseases.  Her research interests include drug metabolism and drug response in inflammatory bowel disease, with a particular focus on genetic markers of drug response.

Recent Publications

Zhu CN, Friedland J, Yan B, Wilson A, Gregor J, Jairath V, Sey M. Presence of Melena in Obscure Gastrointestinal Bleeding Predicts Bleeding in the Proximal Small Intestine. Dig Dis Sci, 2018 May 1; 63 (5): 1280-1285, Coauthor, DOI: 10.1007/s10620-018-5003-x.

Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, Sey M, Beaton M, McIntosh K, Teft WA, Kim RB. Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors’ reply. Aliment Pharmacol Ther. 2018 Apr 1, 47. (7): p.1044-1045, First author, DOI: 10.1111/apt.14562.

Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, Sey M, Beaton M, McIntosh K, Teft WA, Kim RB. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 2018 Mar 1; 47 (5): 615-620, Principal Author, DOI: 10.1111/apt.14483.

Wilson A, Tirona RG, Kim RB. CYP3A4 Activity is Markedly Lower in Patients with Crohn’s Disease. Inflamm Bowel Dis, 2017 Mar 15, Principal Author, DOI: 10.1097/MIB.0000000000001062.

Teft WA, Morse BL, Leake BF, Wilson A, Mansell SE, Hegele RA, Ho RH, Kim RB. Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. Mol Pharm, 2017 Jan 3; 14 (1): 310-318, Co-Author, DOI: 10.1021/acs.molpharmaceut.6b00937.

McLean C, Wilson A, Kim RB. Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant? J Clin Pharmacol, 2016 Jul 1; 56 Suppl 7: S40-58, Coauthor, DOI: 10.1002/jcph.691.

Wilson A, McLean C, Kim RB. Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis. Curr Opin Lipidol, 2016 Apr 1; 27 (2): 148-54,Principal Author, DOI: 10.1097/MOL.0000000000000274.